Tudor Investment Corp ET AL Acquires New Stake in Masimo Corporation $MASI

Tudor Investment Corp ET AL acquired a new stake in Masimo Corporation (NASDAQ:MASI) during the third quarter, Holdings Channel reports. The fund acquired 31,641 shares of the medical equipment provider’s stock, valued at approximately $4,669,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jupiter Asset Management Ltd. acquired a new stake in shares of Masimo in the third quarter valued at about $12,491,000. American Century Companies Inc. boosted its position in Masimo by 10.6% during the third quarter. American Century Companies Inc. now owns 168,341 shares of the medical equipment provider’s stock worth $24,839,000 after acquiring an additional 16,113 shares during the last quarter. 4D Advisors LLC boosted its position in Masimo by 50.0% during the second quarter. 4D Advisors LLC now owns 45,000 shares of the medical equipment provider’s stock worth $7,570,000 after acquiring an additional 15,000 shares during the last quarter. ING Groep NV purchased a new stake in Masimo during the 3rd quarter valued at about $3,069,000. Finally, Citigroup Inc. raised its holdings in Masimo by 133.5% in the 3rd quarter. Citigroup Inc. now owns 116,672 shares of the medical equipment provider’s stock valued at $17,215,000 after acquiring an additional 66,710 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 price objective on Masimo in a research report on Tuesday, February 17th. Wells Fargo & Company raised Masimo to a “hold” rating in a research note on Wednesday, March 18th. Finally, Wolfe Research cut Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $181.17.

Masimo Stock Performance

NASDAQ:MASI opened at $178.09 on Thursday. The company’s 50-day moving average is $158.49 and its two-hundred day moving average is $147.92. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $179.00. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. The firm has a market capitalization of $9.57 billion, a price-to-earnings ratio of -16.90, a PEG ratio of 1.81 and a beta of 1.21.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.